TG Therapeutics Expects Briumvi Revenue of $825M to $850M in FY26
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Should l Buy TGTX?
Source: stocktwits
- Market Opportunity: CEO Michael S. Weiss stated that Briumvi has a 'multi-billion dollar opportunity,' with U.S. revenue expected to reach between $825 million and $850 million in FY26, representing a significant portion of the company's overall revenue.
- Revenue Expectations: The company anticipates total revenue of approximately $616 million for FY25, including $594 million from Briumvi sales in the U.S., exceeding Wall Street's estimate of $606.03 million, indicating robust market demand.
- Product Development: TG Therapeutics is developing a subcutaneous formulation of Briumvi to enhance administration ease, which, if approved, is expected to drive revenue acceleration in the short to mid-term and strengthen market positioning.
- Stock Market Reaction: Following the positive revenue outlook, TG Therapeutics shares rallied 7% in after-hours trading, reflecting strong investor confidence in the company's growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 28.420
Low
15.00
Averages
43.50
High
60.00
Current: 28.420
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleus Capital Increases Stake in Celcuity
- Share Increase: Soleus Capital Management disclosed a purchase of 629,398 shares of Celcuity in an SEC filing, raising its total holdings to over 1.8 million shares valued at $180.36 million, indicating strong confidence in the company.
- Asset Allocation Shift: Celcuity now accounts for 6.7% of Soleus Capital's AUM, becoming its third-largest holding among 95 positions, reflecting investor interest in the biotechnology sector.
- Stock Performance: Celcuity's stock price surged 745% over the past year, significantly outperforming the S&P 500's 14.4% and NASDAQ Composite's 15.7%, highlighting strong market expectations for its future potential.
- Risk Advisory: Despite Celcuity's impressive stock performance, the company currently generates no revenue, necessitating caution from investors regarding inherent risks, as the stock's value is heavily reliant on drug approvals and future profitability prospects.
See More
TG Therapeutics Launches NextInMS Platform to Support MS Patients
- Briumvi Growth Driver: TG Therapeutics projects global revenue of $825 million to $850 million in 2026, with U.S. net product revenue from Briumvi expected to be in the same range, underscoring the drug's pivotal role in multiple sclerosis treatment and driving the company's future financial performance.
- New Platform Launch: The company launched NextInMS.com to foster open conversations among MS patients, caregivers, and healthcare professionals, leveraging Christina Applegate's personal experience to enhance patient awareness and build brand trust.
- Positive Market Reaction: JPMorgan and Goldman Sachs adjusted TG Therapeutics' price targets to $46 and $39, respectively, indicating upside potentials of 59% and 35%, reflecting market optimism regarding the company's growth prospects.
- Clinical Trial Progress: TG Therapeutics completed enrollment in the Phase 3 Enhance trial for Briumvi, with topline data expected in mid-2026, and additional studies may expand Briumvi's indications, enhancing its competitive position in the market.
See More
TG Therapeutics Partners with Christina Applegate to Raise MS Awareness
- Collaboration Initiative: TG Therapeutics has partnered with actress Christina Applegate to launch a national awareness campaign for multiple sclerosis (MS), aiming to spark deeper conversations about the disease through her personal experiences, thereby helping patients better understand and cope with the challenges of living with MS.
- New Platform Launch: The new platform, www.NextInMS.com, will serve as a hub for patients to share experiences and access information, featuring Christina's personal insights along with educational content from MS experts, designed to foster open dialogue among patients, caregivers, and healthcare professionals.
- Advocacy for Honest Dialogue: Christina Applegate emphasizes the complexity of MS, stating, “It’s not something you neatly figure out,” and through her involvement, TG Therapeutics aims to break down misconceptions about MS and enhance public awareness of the disease.
- Company Commitment: TG Therapeutics CEO Michael S. Weiss stated that the company is dedicated to innovation and supporting patient needs, ensuring that while developing new therapies, the voices of patients remain at the forefront to drive better treatment and support resources.
See More
TG Therapeutics Presents BRIUMVI Data at ACTRIMS Annual Meeting
- Clinical Data Presentation: TG Therapeutics showcased clinical data on BRIUMVI (ublituximab-xiiy) at the ACTRIMS annual meeting in San Diego, California, particularly updates from the ENABLE study, emphasizing the company's ongoing commitment to advancing the understanding of MS and supporting the patient community.
- Study Design Overview: The company introduced the design of the ULTIMATE I and II randomized double-blind clinical trials for patients with relapsing multiple sclerosis (RMS), which enrolled a total of 1,094 patients, aimed at evaluating the efficacy and safety of BRIUMVI.
- International Participation: The ULTIMATE I and II trials were conducted across 10 countries, demonstrating TG Therapeutics' global reach and contribution to MS treatment, further solidifying its position in the biopharmaceutical industry.
- Novel Drug Advantages: BRIUMVI, as a novel monoclonal antibody targeting CD20-positive B cells, utilizes glycoengineering to achieve efficient B-cell depletion at low doses, expected to provide more effective treatment options for RMS patients and drive future market growth for the company.
See More
Hussman Strategic Advisors Exits Entire Position in TG Therapeutics
- Position Change: Hussman Strategic Advisors disclosed in an SEC filing that it sold its entire position of 126,000 shares in TG Therapeutics, which previously represented 1.0% of its assets under management, indicating a cautious outlook on the company's future performance.
- Financial Performance: TG Therapeutics reported preliminary fourth-quarter revenue of $182 million for its main product as of January 30, and despite a significant 92.8% year-over-year growth to $161.7 million in the third quarter, the overall performance could not offset the 11.8% decline in its stock over the past year.
- Market Comparison: The underperformance of TG Therapeutics' stock, losing 11.8%, contrasts sharply with the Nasdaq Composite and S&P 500's gains of 20% and 15.8%, respectively, highlighting a lack of competitive edge in the biotechnology sector that may pose higher risks for investors.
- Investor Implications: The complete exit by Hussman suggests a diminishing confidence in TG Therapeutics, prompting investors to closely monitor the company's future strategic partnerships and clinical program developments to assess potential growth opportunities in oncology and immunology markets.
See More
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries
- Price Target Increase: Goldman Sachs raised TG Therapeutics' price target from $37 to $39 while maintaining a 'neutral' rating, indicating over a 32% upside potential, reflecting market optimism regarding the company's future growth prospects.
- Briumvi Market Performance: CEO Michael Weiss stated that Briumvi is now available in 16 countries, with over 20,000 patients prescribed to date, primarily in the U.S., laying a solid foundation for future revenue growth for the company.
- Revenue Expectations: The company anticipates Briumvi's U.S. revenue to range between $825 million and $850 million, which will be a major driver of overall revenue, with a forecast of $875 million to $900 million by 2026, indicating strong market demand.
- Improved Retail Sentiment: According to Stocktwits data, retail sentiment on TG Therapeutics has improved from 'bullish' to 'extremely bullish' over the past month, with message volume surging over 500% in the last week, demonstrating strong investor interest in the stock.
See More
Soleus Capital Increases Stake in Celcuity
- Share Increase: Soleus Capital Management disclosed a purchase of 629,398 shares of Celcuity in an SEC filing, raising its total holdings to over 1.8 million shares valued at $180.36 million, indicating strong confidence in the company.
- Asset Allocation Shift: Celcuity now accounts for 6.7% of Soleus Capital's AUM, becoming its third-largest holding among 95 positions, reflecting investor interest in the biotechnology sector.
- Stock Performance: Celcuity's stock price surged 745% over the past year, significantly outperforming the S&P 500's 14.4% and NASDAQ Composite's 15.7%, highlighting strong market expectations for its future potential.
- Risk Advisory: Despite Celcuity's impressive stock performance, the company currently generates no revenue, necessitating caution from investors regarding inherent risks, as the stock's value is heavily reliant on drug approvals and future profitability prospects.
See More
TG Therapeutics Launches NextInMS Platform to Support MS Patients
- Briumvi Growth Driver: TG Therapeutics projects global revenue of $825 million to $850 million in 2026, with U.S. net product revenue from Briumvi expected to be in the same range, underscoring the drug's pivotal role in multiple sclerosis treatment and driving the company's future financial performance.
- New Platform Launch: The company launched NextInMS.com to foster open conversations among MS patients, caregivers, and healthcare professionals, leveraging Christina Applegate's personal experience to enhance patient awareness and build brand trust.
- Positive Market Reaction: JPMorgan and Goldman Sachs adjusted TG Therapeutics' price targets to $46 and $39, respectively, indicating upside potentials of 59% and 35%, reflecting market optimism regarding the company's growth prospects.
- Clinical Trial Progress: TG Therapeutics completed enrollment in the Phase 3 Enhance trial for Briumvi, with topline data expected in mid-2026, and additional studies may expand Briumvi's indications, enhancing its competitive position in the market.
See More
TG Therapeutics Partners with Christina Applegate to Raise MS Awareness
- Collaboration Initiative: TG Therapeutics has partnered with actress Christina Applegate to launch a national awareness campaign for multiple sclerosis (MS), aiming to spark deeper conversations about the disease through her personal experiences, thereby helping patients better understand and cope with the challenges of living with MS.
- New Platform Launch: The new platform, www.NextInMS.com, will serve as a hub for patients to share experiences and access information, featuring Christina's personal insights along with educational content from MS experts, designed to foster open dialogue among patients, caregivers, and healthcare professionals.
- Advocacy for Honest Dialogue: Christina Applegate emphasizes the complexity of MS, stating, “It’s not something you neatly figure out,” and through her involvement, TG Therapeutics aims to break down misconceptions about MS and enhance public awareness of the disease.
- Company Commitment: TG Therapeutics CEO Michael S. Weiss stated that the company is dedicated to innovation and supporting patient needs, ensuring that while developing new therapies, the voices of patients remain at the forefront to drive better treatment and support resources.
See More
TG Therapeutics Presents BRIUMVI Data at ACTRIMS Annual Meeting
- Clinical Data Presentation: TG Therapeutics showcased clinical data on BRIUMVI (ublituximab-xiiy) at the ACTRIMS annual meeting in San Diego, California, particularly updates from the ENABLE study, emphasizing the company's ongoing commitment to advancing the understanding of MS and supporting the patient community.
- Study Design Overview: The company introduced the design of the ULTIMATE I and II randomized double-blind clinical trials for patients with relapsing multiple sclerosis (RMS), which enrolled a total of 1,094 patients, aimed at evaluating the efficacy and safety of BRIUMVI.
- International Participation: The ULTIMATE I and II trials were conducted across 10 countries, demonstrating TG Therapeutics' global reach and contribution to MS treatment, further solidifying its position in the biopharmaceutical industry.
- Novel Drug Advantages: BRIUMVI, as a novel monoclonal antibody targeting CD20-positive B cells, utilizes glycoengineering to achieve efficient B-cell depletion at low doses, expected to provide more effective treatment options for RMS patients and drive future market growth for the company.
See More
Hussman Strategic Advisors Exits Entire Position in TG Therapeutics
- Position Change: Hussman Strategic Advisors disclosed in an SEC filing that it sold its entire position of 126,000 shares in TG Therapeutics, which previously represented 1.0% of its assets under management, indicating a cautious outlook on the company's future performance.
- Financial Performance: TG Therapeutics reported preliminary fourth-quarter revenue of $182 million for its main product as of January 30, and despite a significant 92.8% year-over-year growth to $161.7 million in the third quarter, the overall performance could not offset the 11.8% decline in its stock over the past year.
- Market Comparison: The underperformance of TG Therapeutics' stock, losing 11.8%, contrasts sharply with the Nasdaq Composite and S&P 500's gains of 20% and 15.8%, respectively, highlighting a lack of competitive edge in the biotechnology sector that may pose higher risks for investors.
- Investor Implications: The complete exit by Hussman suggests a diminishing confidence in TG Therapeutics, prompting investors to closely monitor the company's future strategic partnerships and clinical program developments to assess potential growth opportunities in oncology and immunology markets.
See More
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries
- Price Target Increase: Goldman Sachs raised TG Therapeutics' price target from $37 to $39 while maintaining a 'neutral' rating, indicating over a 32% upside potential, reflecting market optimism regarding the company's future growth prospects.
- Briumvi Market Performance: CEO Michael Weiss stated that Briumvi is now available in 16 countries, with over 20,000 patients prescribed to date, primarily in the U.S., laying a solid foundation for future revenue growth for the company.
- Revenue Expectations: The company anticipates Briumvi's U.S. revenue to range between $825 million and $850 million, which will be a major driver of overall revenue, with a forecast of $875 million to $900 million by 2026, indicating strong market demand.
- Improved Retail Sentiment: According to Stocktwits data, retail sentiment on TG Therapeutics has improved from 'bullish' to 'extremely bullish' over the past month, with message volume surging over 500% in the last week, demonstrating strong investor interest in the stock.
See More
